Wealth Enhancement Advisory Services LLC Has $27.84 Million Stock Holdings in Cigna Group $CI

Wealth Enhancement Advisory Services LLC trimmed its stake in shares of Cigna Group (NYSE:CI) by 17.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 90,629 shares of the health services provider’s stock after selling 18,940 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Cigna Group were worth $27,836,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of CI. Pathway Financial Advisers LLC lifted its position in shares of Cigna Group by 2.3% during the 2nd quarter. Pathway Financial Advisers LLC now owns 1,501 shares of the health services provider’s stock worth $496,000 after buying an additional 34 shares during the period. Armstrong Advisory Group Inc. raised its stake in Cigna Group by 17.7% during the third quarter. Armstrong Advisory Group Inc. now owns 226 shares of the health services provider’s stock worth $65,000 after acquiring an additional 34 shares in the last quarter. HM Payson & Co. lifted its holdings in shares of Cigna Group by 0.9% during the third quarter. HM Payson & Co. now owns 3,785 shares of the health services provider’s stock valued at $1,091,000 after acquiring an additional 35 shares during the period. Carr Financial Group Corp boosted its stake in shares of Cigna Group by 5.3% in the 3rd quarter. Carr Financial Group Corp now owns 709 shares of the health services provider’s stock valued at $204,000 after purchasing an additional 36 shares in the last quarter. Finally, Natural Investments LLC boosted its stake in shares of Cigna Group by 2.0% in the 3rd quarter. Natural Investments LLC now owns 1,843 shares of the health services provider’s stock valued at $531,000 after purchasing an additional 36 shares in the last quarter. 86.99% of the stock is currently owned by institutional investors.

Cigna Group Price Performance

Shares of CI stock opened at $274.84 on Thursday. Cigna Group has a 1 year low of $239.51 and a 1 year high of $350.00. The company has a current ratio of 0.76, a quick ratio of 0.76 and a debt-to-equity ratio of 0.74. The firm’s 50 day moving average is $274.07 and its 200-day moving average is $286.09. The firm has a market capitalization of $73.42 billion, a price-to-earnings ratio of 12.12, a PEG ratio of 0.96 and a beta of 0.26.

Cigna Group (NYSE:CI) last issued its quarterly earnings results on Thursday, October 30th. The health services provider reported $7.83 earnings per share for the quarter, beating analysts’ consensus estimates of $7.64 by $0.19. Cigna Group had a net margin of 2.29% and a return on equity of 18.80%. The business had revenue of $69.57 billion during the quarter, compared to analyst estimates of $66.40 billion. During the same quarter last year, the business posted $7.51 earnings per share. Cigna Group’s revenue for the quarter was up 9.5% compared to the same quarter last year. Cigna Group has set its FY 2025 guidance at 29.600- EPS. Sell-side analysts forecast that Cigna Group will post 29.77 EPS for the current fiscal year.

Insider Transactions at Cigna Group

In other news, CEO David Cordani acquired 4,134 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was purchased at an average cost of $241.88 per share, for a total transaction of $999,931.92. Following the completion of the transaction, the chief executive officer directly owned 157,935 shares in the company, valued at $38,201,317.80. This trade represents a 2.69% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. TD Cowen set a $333.00 target price on shares of Cigna Group in a research report on Monday, December 15th. Wolfe Research decreased their price objective on shares of Cigna Group from $345.00 to $325.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 15th. Wells Fargo & Company dropped their price objective on shares of Cigna Group from $354.00 to $300.00 and set an “equal weight” rating for the company in a report on Wednesday, November 5th. Truist Financial boosted their target price on Cigna Group from $310.00 to $320.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Finally, Cantor Fitzgerald reduced their target price on Cigna Group from $365.00 to $325.00 in a report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $330.36.

Cigna Group Company Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.